Indian Life-Cycle Insights Case Study: Trajenta and Trajenta Duo
Simultaneous Litigation Events in Courts Across India and the Effect on Generic Entry
In India, patent litigation can simultaneously move through a number of courts, all of which can impact loss-of-exclusivity timing. The multiplicity of proceedings makes it critical to be physically present in the courtroom to understand and analyze the legal proceedings in which a drug may be involved. Through our latest report on Boehringer Ingelheim’s Trajenta (linagliptin) and Trajenta Duo (linagliptin/metformin hydrochloride), learn how the same drug was litigated for patent infringement and revocation actions in the Delhi, Bombay (Mumbai), Himachal Pradesh, Telangana, and Madras (Chennai) High Courts by various generic drug manufacturers.